Hong Kong expects findings of inquiry into BioNTech vaccine packaging defects next week: SCMP
Reuters
Published Mar 27, 2021 03:35AM ET
(Reuters) - Hong Kong expects the preliminary findings of an investigation into packaging defects of the COVID-19 vaccine developed by Germany's BioNTech SE (NASDAQ:BNTX) as soon as next week, the South China Morning Post reported on Saturday, citing Secretary for the Civil Service Patrick Nip (https://
Nip said he had personally requested senior management of China's Fosun Pharma to ship a new batch of the vaccines to Hong Kong if there were safety concerns with the existing ones, the SCMP reported.
The BioNTech vaccine is distributed in Hong Kong and Macau through a partnership with Fosun Pharma. BioNTech partners with Pfizer Inc (NYSE:PFE) in markets outside greater China.
BioNTech said on March 24 it had decided to pause further vaccination with the batch until the investigation is complete as a precautionary measure and that no other batches shipped to other regions are affected by this investigation.
People are expected to get their booster dose before mid-April, Nip said on a radio show, according to the SCMP report. "We will give priority to those who need the second dose when we assign the new time slots and venues once the vaccinations with BioNTech can resume,” the report added.
Hong Kong and Macau halted the use of a COVID-19 vaccine developed by BioNTech on Wednesday, citing defective packaging, in a move that triggered scenes of confusion in inoculation centres across the city.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.